Delayed diagnosis of adult indolent systemic mastocytosis.

Dermatol Reports

Private Practice, Broenderslev, Denmark.

Published: February 2014

Systemic mastocytosis (SM) is a rare, heterogeneous disorder characterized by infiltration and accumulation of mast cells within multiple organs, most commonly the skin. Given the rarity of the disease and the fact that many of its symptoms are shared by more common disorders, a diagnosis may be delayed or hindered. These patients have an elevated risk of developing potentially life-threatening anaphylactoid reactions, thus underscoring the importance of keeping SM in mind as a differential diagnosis when a patient presents with chronic, itchy skin lesions and a history of multiple allergic reactions to bites, drugs, and anesthesia. We present a case illustrating that features of SM common to many disorders may hinder or delay its diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224005PMC
http://dx.doi.org/10.4081/dr.2014.5199DOI Listing

Publication Analysis

Top Keywords

systemic mastocytosis
8
common disorders
8
delayed diagnosis
4
diagnosis adult
4
adult indolent
4
indolent systemic
4
mastocytosis systemic
4
mastocytosis rare
4
rare heterogeneous
4
heterogeneous disorder
4

Similar Publications

Background: Systemic mastocytosis (SM) diagnosis requires the presence of 3 minor criteria or 1 major and 1 minor criterion according to the WHO 2016 classification. The aim of this study was to characterize patients with 1 or 2 minor SM criteria including mutation and/or aberrant expression of CD2 and/or CD25 on bone marrow (BM) mast cells (MCs), but without MC activation syndrome (MCAS) criteria.

Methods: We included eligible patients from two countries diagnosed between 2011 and 2021.

View Article and Find Full Text PDF

Mastocytosis is a rare neoplastic disease of the bone marrow. Common symptoms like urticaria, diarrhea, bronchspasm and flushing are caused by mast cell degranulation and are mostly based on mast cell mediator release and Th2 type inflammation that occurs frequently in these patients. Psychological disorders are more prevalent in patients with systemic mastocytosis, though little is known about the mechanism behind this.

View Article and Find Full Text PDF

Systemic mastocytosis (SM) is a rare disease and has had significant discoveries in its biology, prognostication, and management in the past two decades. The latest update of the WHO classification and the new ICC classification are current standards in the diagnosis and prognostication of SM. In clinical practice, SM can be divided into two main categories: non-advanced SM (nonAdvSM) and advanced SM (AdvSM).

View Article and Find Full Text PDF
Article Synopsis
  • CD2, CD25, and CD30 expression in extracutaneous mast cells is a minor diagnostic criterion for systemic mastocytosis (SM), as categorized by the World Health Organization and International Consensus Classification.
  • A study of 5,034 patients revealed that lower percentages of CD2, CD25, and/or CD30 in mast cells are seen in indolent SM compared to advanced forms like aggressive SM and mast cell leukemia.
  • The absence of CD2 in mast cells is linked to significantly lower overall survival and indicates the potential for disease spread outside the bone marrow to organs like the spleen and liver.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!